Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.

Abstract:

BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Registry. Cases included those diagnosed between 1990 and 2005. We analyzed race, stage, age of diagnosis, and treatment received: chemotherapy, radiation, surgery, and hormonal therapy. A Cox proportional hazards model was used to determine differences in OS. RESULTS:Compared with 670 white women, 489 black women were more likely to be younger, have later-stage disease at diagnosis, and were less likely to have received hormonal therapy. Both groups received similar rates of radiation, surgery, and chemotherapy. Black women had significantly poorer OS (adjusted hazard ratio, 1.35; 95% CI, 1.12-1.63). White women had a 5-year OS of 54% compared with 45% in black women (P = .0031). Having received radiation, surgery, or chemotherapy was not associated with OS. White women were more likely to have received hormonal therapy, which had a significant protective effect. However, a stratified analysis (between those who received hormonal therapy and those who did not) showed similar results, whereas black women experienced poorer OS in both strata. CONCLUSION:Black women with breast cancer had a significantly poorer OS compared with white women. White women received more hormonal therapy, which had a protective effect. There were no differences in treatment received regarding radiation, surgery, or chemotherapy, and these treatments were not associated with OS. The reasons for racial disparities in breast cancer OS remain complex.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Barcenas CH,Wells J,Chong D,French J,Looney SW,Samuel TA

doi

10.3816/CBC.2010.n.008

subject

Has Abstract

pub_date

2010-02-01 00:00:00

pages

59-63

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)70008-8

journal_volume

10

pub_type

杂志文章
  • Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.

    abstract:PURPOSE:The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC). PATIENTS AND METHODS:Fifty-eight patients with IBC were treated between January 1994 and July 2002. Median age was 49 years. Thirty-eight patients had baseline...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.045

    authors: Gonzalez-Angulo AM,Guarneri V,Gong Y,Cristofanilli M,Morales-Vasquez F,Sneige N,Hortobagyi GN,Esteva FJ

    更新日期:2006-10-01 00:00:00

  • Cardiac toxicity of ErbB2-targeted therapies: what do we know?

    abstract::The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2008.s.007

    authors: Perez EA

    更新日期:2008-03-01 00:00:00

  • Aromatase inhibitors for the treatment and prevention of breast cancer.

    abstract::In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.006

    authors: Kalidas M,Brown P

    更新日期:2005-04-01 00:00:00

  • Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.

    abstract::Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.s.006

    authors: Mamounas EP,Geyer CE Jr,Swain SM

    更新日期:2004-01-01 00:00:00

  • The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors.

    abstract:BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.07.007

    authors: Choi WJ,Cha JH,Kim HH,Shin HJ,Chae EY

    更新日期:2016-12-01 00:00:00

  • Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

    abstract:BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.011

    authors: Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

    更新日期:2019-02-01 00:00:00

  • Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer.

    abstract::Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2003.n.030

    authors: Truong MT,Hirsch AE,Formenti SC

    更新日期:2003-10-01 00:00:00

  • Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence.

    abstract::The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2008.n.038

    authors: Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

    更新日期:2008-08-01 00:00:00

  • A new technique that complements sentinel lymph node biopsy: lymph node dissection under the intercostobrachial nerves in early-stage breast cancer.

    abstract:BACKGROUND:Arm lymphedema is a common complication after axillary lymph node dissection (ALND), and there is no effective treatment. The clinical significance of sentinel lymph node biopsy (SLNB) is to avoid the risk of arm lymphedema caused by ALND in cases in which the nodes are negative for cancer cells. In develope...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.10.005

    authors: Li J,Jia S,Zhang W,Zhang Y,Qiu F,Xue J,Gu X

    更新日期:2013-06-01 00:00:00

  • A Guide to Prepectoral Breast Reconstruction: A New Dimension to Implant-based Breast Reconstruction.

    abstract::Acellular dermal matrix has revolutionized implant-based breast reconstruction. Breast reconstruction has evolved from the traditional submuscular to the new prepectoral implant based (also known as muscle-sparing) reconstruction. The new technique is emerging as a highly popular surgery owing to its more minimal appr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.11.009

    authors: Vidya R,Iqbal FM

    更新日期:2017-07-01 00:00:00

  • Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancer.

    abstract:BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.014

    authors: Tchou J,Greshock J,Bergey MR,Sonnad SS,Sargen M,Weinstein S,Czerniecki BJ,Boraas M,Fraker DL,Rosato E,Fox K,Weber B,Solin LJ

    更新日期:2008-04-01 00:00:00

  • Outcome after ipsilateral breast tumor recurrence in patients with early-stage breast cancer treated with accelerated partial breast irradiation.

    abstract:PURPOSE:Limited outcomes exist in patients who develop an ipsilateral breast tumor recurrence (IBTR) after accelerated partial breast irradiation (APBI). The purpose of this study was to evaluate these outcomes and patterns of failure in our cohort of patients undergoing APBI. METHODS AND MATERIALS:A total of 534 pati...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.09.006

    authors: Shah C,Wilkinson JB,Jawad M,Wobb J,Berry S,Mitchell C,Wallace M,Vicini FA

    更新日期:2012-12-01 00:00:00

  • Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

    abstract::Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/cbc.2002.s.004

    authors: O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

    更新日期:2002-05-01 00:00:00

  • Cysteine rhenium colloid: a novel radiocolloid for identifying sentinel lymph nodes in breast cancer surgery.

    abstract:BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.07.006

    authors: Kidane B,Zabel PL,Gupta V,Whiston C,Wright F,Brackstone M

    更新日期:2015-02-01 00:00:00

  • Physical Exercise Positively Influences Breast Cancer Evolution.

    abstract::Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2017.05.003

    authors: Adraskela K,Veisaki E,Koutsilieris M,Philippou A

    更新日期:2017-10-01 00:00:00

  • Timing of Postmastectomy Reconstruction Does Not Impair Breast Cancer-Specific Survival: A Population-Based Study.

    abstract:BACKGROUND:Debate remains over the optimal timing of breast reconstruction after mastectomy. Immediate reconstruction has demonstrated superior psychosocial and aesthetic outcomes, but might delay adjuvant therapy. Conversely, delayed reconstruction allows for timely initiation of adjuvant therapy, but with potentially...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.003

    authors: Bezuhly M,Wang Y,Williams JG,Sigurdson LJ

    更新日期:2015-12-01 00:00:00

  • Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

    abstract::Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.014

    authors: Gordon DH

    更新日期:2005-06-01 00:00:00

  • Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results.

    abstract:BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.015

    authors: de Vita R,Buccheri EM,Villanucci A,Pozzi M

    更新日期:2019-04-01 00:00:00

  • JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.

    abstract:BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.05.006

    authors: Chen M,Pockaj B,Andreozzi M,Barrett MT,Krishna S,Eaton S,Niu R,Anderson KS

    更新日期:2018-10-01 00:00:00

  • The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08).

    abstract:BACKGROUND:Despite margin-negative breast-conserving surgery (BCS), phyllodes tumors (PT) of the breast show high local recurrence (LR) rates. In this study we aimed to assess the site and grade of LR to identify high-risk patients after initial treatment of malignant and borderline PT using BCS alone. PATIENTS AND ME...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2019.04.003

    authors: Choi N,Kim K,Shin KH,Kim Y,Moon HG,Park W,Choi DH,Kim SS,Ahn SD,Kim TH,Chun M,Kim YB,Kim S,Choi BO,Kim JH

    更新日期:2019-10-01 00:00:00

  • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.

    abstract:BACKGROUND:We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer in Japan remains unclear. PATIENTS AND METHODS:The study subjects were female patients with primary unilateral invasive breast cancer considered as candidates for breast-conserving surgery w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.08.004

    authors: Inuzuka M,Watanabe C,Yokoyama S,Kuwayama T,Akashi-Tanaka S,Arai M,Nakamura S,Registration Committee of the Japanese HBOC consortium.

    更新日期:2020-08-20 00:00:00

  • Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.

    abstract::Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.05.012

    authors: Tang Y,Wang Y,Kiani MF,Wang B

    更新日期:2016-10-01 00:00:00

  • Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.

    abstract::Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.029

    authors: Robson M

    更新日期:2004-10-01 00:00:00

  • A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.

    abstract:PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.027

    authors: Yerushalmi R,Hayes MM,Gelmon KA,Chia S,Bajdik C,Norris B,Speers C,Hassell P,O'Reilly SE,Allan S,Shenkier TN

    更新日期:2009-08-01 00:00:00

  • Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

    abstract:BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2018.12.012

    authors: Ortega V,Antón A,Garau I,Afonso N,Calvo L,Fernández Y,Martínez-García M,Blanco E,Zamora P,García M,Illarramendi JJ,Rodríguez Sánchez CA,Sampayo M,Aguirre E,Pérez-García JM,Cortés J,Llombart-Cussac A

    更新日期:2019-04-01 00:00:00

  • A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

    abstract:BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.02.006

    authors: Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

    更新日期:2019-06-01 00:00:00

  • A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

    abstract:BACKGROUND:The purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). PATIENTS AND METHODS:Eligible patients had HR+/human epidermal growth factor receptor 2-negat...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.01.012

    authors: Barroso-Sousa R,Krop IE,Trippa L,Tan-Wasielewski Z,Li T,Osmani W,Andrews C,Dillon D,Richardson ET 3rd,Pastorello RG,Winer EP,Mittendorf EA,Bellon JR,Schoenfeld JD,Tolaney SM

    更新日期:2020-06-01 00:00:00

  • Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?

    abstract:OBJECTIVE:The Hungarian National Institute of Oncology has just closed a single-center randomized clinical study. The Optimal Treatment of the Axilla-Surgery or Radiotherapy (OTOASOR) trial compares completion axillary lymph node dissection (cALND) with regional nodal irradiation (RNI) in patients with sentinel lymph n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.04.004

    authors: Sávolt A,Polgár C,Musonda P,Mátrai Z,Rényi-Vámos F,Tóth L,Kásler M,Péley G

    更新日期:2013-10-01 00:00:00

  • Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?

    abstract::This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Di Leo A,Isola J

    更新日期:2003-08-01 00:00:00

  • Breast Cancer and Ovulation Induction Treatments.

    abstract:BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Behesh...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.03.003

    authors: Taheripanah R,Balash F,Anbiaee R,Mahmoodi M,Akbari Sene A

    更新日期:2018-10-01 00:00:00